BioCardia logo

BioCardiaNASDAQ: BCDA

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

13 November 1996

Next earnings report:

27 March 2025

Last dividends:

N/A

Next dividends:

N/A
$10.45 M
-83%vs. 3y high
18%vs. sector
-vs. 3y high
-vs. sector
-89%vs. 3y high
74%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | 11 min ago
$2.28+$0.08(+3.64%)

Dividend

No data over the past 3 years
$20.00 K$20.00 K

Analysts recommendations

Institutional Ownership

BCDA Latest News

BioCardia, Inc. (BCDA) Q3 2024 Earnings Call Transcript
seekingalpha.com13 November 2024 Sentiment: NEUTRAL

BioCardia, Inc. (NASDAQ:BCDA ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Miranda Peto - Investor Relations Peter Altman - President and CEO David McClung - Chief Financial Officer Conference Call Participants Joe Pantginis - H.C. Wainwright Kumar Raja - Brookline Capital Markets Operator Good afternoon, ladies and gentlemen.

BioCardia Regains Full Compliance with Nasdaq Listing Requirements
globenewswire.com18 September 2024 Sentiment: POSITIVE

SUNNYVALE, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today that the Company has regained full compliance with the Nasdaq Capital Market's Listing Requirements as required by the Hearing Panel's (the “Panel”) decision on May 13, 2024.

BioCardia Announces FDA Market Clearance of Morph® DNA™ Steerable Introducer Product Family
globenewswire.com29 August 2024 Sentiment: POSITIVE

SUNNYVALE, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today that the Food and Drug Administration (FDA) has cleared BioCardia to market the Morph DNA Steerable Introducer product family, subject to the general controls provisions of the Federal Food, Drug, and Cosmetic Act.

BioCardia, Inc. (BCDA) Q2 2024 Earnings Call Transcript
seekingalpha.com13 August 2024 Sentiment: NEUTRAL

BioCardia, Inc. (NASDAQ:BCDA ) Q2 2024 Earnings Conference Call August 13, 2024 4:30 PM ET Company Participants Miranda Peto - Investor Relations Peter Altman - President and CEO David McClung - Chief Financial Officer Conference Call Participants Joe Pantginis - H.C. Wainwright Laura Suriel - Alliance Global Partners Kevin Marshall - Innovative Financial Group Operator Ladies and gentlemen, thank you for standing by.

BioCardia Reports Second Quarter 2024 Business Highlights and Financial Results
globenewswire.com13 August 2024 Sentiment: POSITIVE

SUNNYVALE, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the second quarter of 2024 and filed its quarterly report on Form 10-Q for the three and six months ended June 30, 2024 with the Securities and Exchange Commission. The Company will also hold a conference call at 4:30 PM ET today in which it will discuss business highlights. Following management's formal remarks, there will be a question-and-answer session.

BioCardia Announces United States Patent Issuance on Intramyocardial Delivery of Cell Aggregates to the Heart Including Minimally Invasive Radial Artery Approach
globenewswire.com07 June 2024 Sentiment: POSITIVE

BioCardia announces that the USPTO has granted Patent No: 11,986,611 titled “Radial and Transendocardial Delivery Catheter,” with a 2036 expiration date.

BioCardia Announces Reverse Stock Split
globenewswire.com21 May 2024 Sentiment: NEUTRAL

SUNNYVALE, Calif., May 21, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that, following approval by the Company's stockholders and its Board of Directors, the Company intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 15 pre-split shares. The reverse stock split will become effective at 12:01 a.m. Eastern Daylight Time on Thursday, May 30, 2024. The Company's common stock will begin trading on a split-adjusted basis when the market opens on Thursday, May 30, 2024. The Company's common stock and warrants will continue to be traded on The Nasdaq Capital Market under the ticker symbols “BCDA” and “BCDAW,” respectively. The reverse stock split is intended to increase the minimum bid price requirement for continued listing on The Nasdaq Capital Market. The Company, however, cannot assure that the price of its common stock after the reverse stock split will reflect the corresponding split ratio, that the price per share following the effective time will be maintained for any period of time, or that the price will remain above the pre-split trading price.

BioCardia, Inc. (BCDA) Q1 2024 Earnings Call Transcript
Seeking Alpha14 May 2024 Sentiment: NEUTRAL

BioCardia, Inc. (NASDAQ: BCDA) Q1 2024 Earnings Conference Call will take place on May 14, 2024 at 4:30 PM ET. Present on the call will be Miranda Peto, Peter Altman, and David McClung. Lander Egaña-Gorroño from H.C. Wainwright will also be participating. Thank you for joining us.

BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024
GlobeNewsWire20 March 2024 Sentiment: POSITIVE

SUNNYVALE, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will report its financial results for the year ended December 31, 2023 and provide a corporate update by conference call on Wednesday, March 27, 2024 at 4:30 PM ET.

BioCardia (BCDA) Soars 168% on FDA Nod to Heart Failure Study
Zacks Investment Research15 November 2023 Sentiment: POSITIVE

The FDA approves BioCardia's (BCDA) phase III study on its CardiAMP cell therapy to treat patients with ischemic heart failure.

  • 1(current)

What type of business is BioCardia?

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.

What sector is BioCardia in?

BioCardia is in the Healthcare sector

What industry is BioCardia in?

BioCardia is in the Biotechnology industry

What country is BioCardia from?

BioCardia is headquartered in United States

When did BioCardia go public?

BioCardia initial public offering (IPO) was on 13 November 1996

What is BioCardia website?

https://www.biocardia.com

Is BioCardia in the S&P 500?

No, BioCardia is not included in the S&P 500 index

Is BioCardia in the NASDAQ 100?

No, BioCardia is not included in the NASDAQ 100 index

Is BioCardia in the Dow Jones?

No, BioCardia is not included in the Dow Jones index

When was BioCardia the previous earnings report?

No data

When does BioCardia earnings report?

The next expected earnings date for BioCardia is 27 March 2025